Easily releasable myofilaments from skeletal and cardiac muscles maintained in vitro. Role in myofibrillar assembly and turnover.
Gentle treatment with an ATP-containing relaxing solution of isolated myofibrils from rat diaphragm, soleus, extensor digitorum longus, and left atria maintained in vitro releases a small amount of myofilaments constituting less than 5% of total myofibrillar protein. Successive extraction of myofibrils produced little further filament release. Releasable myofilaments lack alpha-actinin (Mr = 95,000), certain very high molecular weight proteins (greater than 200,000), and possibly M-line protein but contain other myofibrillar proteins. After pulse-labeling with [3H]leucine for 8 min, specific activity of the myosin heavy chain in the easily releasable myofilaments is 3-6 times higher than the specific activity of myosin heavy chain in the residual myofibrils, although 85-90% of total label is in the myofibrillar myosin. In the absence of protein synthesis, releasable filament specific activity decreases, with a half-time of 60-90 min, to that of the myofibrillar myosin. This labeling pattern appears inconsistent with a simple precursor-product relationship between releasable filaments and myofibrils suggesting that the filaments originate largely from myofibrils. Preincubation of muscles with several factors known to decrease proteolysis, i.e. passive stretch, leupeptin, colchicine, and cycloheximide, reduced the size of the releasable filament fraction. Treatment of muscles with the calcium ionophore A23187, which accelerates proteolysis, and pretreatment of myofibrils with either trypsin or calcium-dependent protease increased filament release. Therefore, the releasable filament fraction may contain intermediates in the breakdown of myofibrils. The labeling kinetics may indicate a mixing of myofilaments within myofibrils which functions in the movement of contractile protein to its possible site of degradation, i.e. the myofibrillar surface.
D000818:Animals; D000001:Calcimycin / Q000494:pharmacology; D002458:Cell Fractionation / Q000379:methods; D005260:Female; D007976:Leupeptins / Q000494:pharmacology; D008970:Molecular Weight; D009124:Muscle Proteins / Q000032:analysis*; D009132:Muscles / Q000648:ultrastructure*; D009206:Myocardium / Q000648:ultrastructure*; D009210:Myofibrils / Q000187:drug effects / Q000648:ultrastructure*; D009218:Myosins / Q000032:analysis; D051381:Rats; D011919:Rats, Inbred Strains; D014357:Trypsin
D007976:Leupeptins; D009124:Muscle Proteins; D000001:Calcimycin; D014357:Trypsin; D009218:Myosins; C032854:leupeptin